GSK Braces For A Hit To Its Vaccines Business Despite A Strong First Quarter

 
• By Jessica Merrill

Stay-at-home restrictions due to COVID-19 have started to impact the company's vaccines business, including the big growth driver Shingrix.

Slowdown, word cube with background.
Sales of GSK's big growth driver Shingrix have slowed in the second quarter • Source: Shutterstock

Vaccines is one pharmaceutical business area that is experiencing challenging commercial dynamics as patients sit out non-essential doctor visits amid the COVID-19 pandemic.

GlaxoSmithKline PLC said it expects significant impacts on sales of Shingrix in the coming months as a result. The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business